SEC Tracker
Get the app

Keenova Therapeutics

Keenova Therapeutics reports Q3 2026 results

Keenova Therapeutics filed an 8-K with the SEC on Nov 10, 2026, 6:37 am ET. Source: the filing on SEC EDGAR.

Item 2.02 Reports results

Form
8-K
Filed
Importance
Major
  1. Acthar Gel net sales of $227 million
  2. XIAFLEX net sales of $164 million
  3. Loss from continuing operations of $96 million
  4. Adjusted EBITDA from continuing operations of $233 million

Written from the 8-K on EDGAR. AI can make mistakes. Check the filing.

Get the appView on EDGAR

Get an email when Keenova Therapeutics files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Data on this page was fetched . The filing on SEC.gov is the record.